PALATINE, IL -- (Marketwired) -- 07/24/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the second quarter 2014 following the close of financial markets on Monday, August 4, 2014. The Company will host a conference call to discuss the results on Tuesday, August 5, 2014 at 8:30 a.m. ET.

To participate in the live conference call, please dial 1-888-505-4369 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 8612011. A replay of the call will be available beginning August 6, 2014 at 11:30 a.m. ET and ending on August 22, 2014 on the company's website, and by dialing 1-888-203-1112 (U.S. and Canada). The replay participant code is 8612011.

About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® Technologies. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved our oxycodone HCl immediate-release tablets which incorporate the AVERSION® Technology. The Company has a development pipeline of additional AVERSION® Technology products containing other opioids.

In December 2012, the Company commenced commercialization of NEXAFED® [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal congestion relief with IMPEDE® Technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine.

Contact:
for Acura Investor Relations
Email Contact
847-705-7709

for Acura Media Relations
Email Contact
847-705-7709

Source: Acura Pharmaceuticals, Inc.

News Provided by Acquire Media